Sensydia

Key People

• Anthony Arnold - President & CEO
• Dr. Aman Mahajan - Founder & Chief Medical Officer
• William Kaiser - Chief Technology Officer
• Rusty Page - President & COO
• William A. Hawkins - Advisor

Assessment

Team

Aspect: 1 successful MedTech entrepreneur
Summary: Led by Anthony Arnold, an experienced MedTech entrepreneur.

Anthony Arnold brings over 25 years of experience in developing successful medical devices, including leadership roles at SetPoint Medical, Boston Scientific, and Medtronic. His expertise positions Sensydia well for navigating the MedTech landscape.

Clinical Need

Aspect: Very Strong
Summary: Addresses critical need for non-invasive cardiac assessment.

Heart disease remains a leading cause of death worldwide. Sensydia's Cardiac Performance System (CPS) offers rapid, non-invasive measurements of key heart performance metrics, potentially reducing hospital readmissions and improving patient outcomes.

Competition

Aspect: Somewhat crowded
Summary: Competes in a market with existing non-invasive cardiac devices.

The market for non-invasive cardiac assessment tools includes several players offering similar technologies. Sensydia's success will depend on differentiating its CPS through superior accuracy, ease of use, and cost-effectiveness.

Technical Challenge

Aspect: Moderate
Summary: Development of accurate non-invasive cardiac metrics is moderately challenging.

Creating a device that accurately measures cardiac performance non-invasively involves complex biosensor technology and sophisticated algorithms. While challenging, Sensydia's team has the expertise to address these technical hurdles.

Patent

Aspect: Strong
Summary: Holds strong patents in non-invasive cardiac assessment technology.

Sensydia has developed proprietary technologies for its CPS, likely securing patents to protect its innovations. This intellectual property provides a competitive edge and potential barriers to entry for competitors.

Financing

Aspect: Well-funded
Summary: Secured significant funding from reputable investors.

Sensydia raised approximately $8 million in 2023 from investors including Orlando Health Ventures, Colle Capital, and Frontier Venture Capital. This funding enables the company to advance its CPS platform towards commercialization.

Regulatory

Aspect: 510k/PMA
Summary: Achieved FDA 510(k) clearance and Breakthrough Device Designation.

In 2018, Sensydia received FDA 510(k) clearance for non-invasive measurement of ejection fraction. In 2022, the CPS was granted Breakthrough Device Designation, facilitating expedited review processes and signaling the device's potential impact.

Opportunity Rollup

Odds of Success

3.2

Peak Market Share

4.2

Segment CAGR

4.4%

Market Segment

Cardiovascular Devices

Market Sub Segment

Non-Invasive Cardiac Monitoring

Key Takeaway

Sensydia's non-invasive Cardiac Performance System addresses a critical need in cardiac care, supported by experienced leadership and strong financial backing, positioning it well in a competitive market.